Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-Anilinoquinazolines

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.50, Iss.6, 2011-06, pp. : 371-403

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles

By >

Clinical Pharmacokinetics, Vol. 50, Iss. 9, 2011-09 ,pp. : 551-603

Adis International

Access to resources Recommend Favorite

Selective tyrosine kinase inhibitors

By Wilkinson S.E. Harris W.

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 287-297

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. : 462-483

Bentham Science Publishers

Access to resources Recommend Favorite

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

By Laird A Douglas Cherrington Julie M

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 51-64

Informa Healthcare

Access to resources Recommend Favorite

Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology

Current Drug Metabolism, Vol. 18, Iss. 3, 2017-03 ,pp. : 186-198

Bentham Science Publishers

Access to resources Recommend Favorite